Last reviewed · How we verify
Anti-H1N1v Vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the H1N1 influenza virus.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the H1N1 influenza virus. Used for Prevention of H1N1 influenza infection.
At a glance
| Generic name | Anti-H1N1v Vaccine |
|---|---|
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Drug class | Inactivated influenza vaccine |
| Target | H1N1 influenza virus hemagglutinin and neuraminidase antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated H1N1 viral antigens that trigger both humoral (antibody-mediated) and cell-mediated immune responses. Upon vaccination, B cells produce neutralizing antibodies against viral surface proteins (hemagglutinin and neuraminidase), while T cells develop memory to recognize and eliminate H1N1-infected cells, providing protection against infection and severe disease.
Approved indications
- Prevention of H1N1 influenza infection
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: